Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
14.30
-0.24 (-1.65%)
Aug 7, 2026, 4:00 PM EDT - Market closed

Immunic Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-109.64-103.23-98.05-99.22-119.49-91.67
Net Income
-104.29-97.17-100.51-93.61-120.41-92.95
Earnings Per Share
-5.08-6.20-10.00-21.10-37.80-39.30
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
186.6315.4835.6746.67116.3786.86
Total Debt
0.150.110.260.640.990.58
Net Cash (Debt)
186.4815.3835.446.04115.3886.28
Net Cash Growth
1223.14%-56.57%-23.09%-60.10%33.73%-31.94%
Net Cash Per Share
9.080.993.5310.3936.2636.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-81.33-85.81-84.77-70.83-65.14-83.23
Capital Expenditures
-0.12-0.16-0.26-0.33-0.11-0.07
Free Cash Flow
-81.45-85.97-85.03-71.16-65.26-83.3
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.